Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

CHICAGO -- Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Recent results from the NRG-NSABP B-51/RTOG 1304 clinical study showed that the addition of regional nodal irradiation (RNI) ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive ...